SUPRIYA LIFESCIENCE Financial Statement Analysis
|
||
|
The Revenues of SUPRIYA LIFESCIENCE have decreased by -13.04% YoY .
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has decreased by -40.83 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SUPRIYA LIFESCIENCE Last 5 Annual Financial Results
[BOM: 543434|NSE : SUPRIYA]
| Standalone | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹461 Cr | ₹530 Cr | ₹391 Cr | ₹312 Cr | ₹278 Cr |
| Expenses | ₹332 Cr | ₹316 Cr | ₹218 Cr | ₹213 Cr | ₹213 Cr |
| Operating Profit (Excl OI) | ₹128 Cr | ₹214 Cr | ₹173 Cr | ₹98 Cr | ₹64 Cr |
| Other Income | ₹9.99 Cr | ₹7.58 Cr | ₹5.01 Cr | ₹11 Cr | ₹8.33 Cr |
| Interest | ₹3.13 Cr | ₹4.20 Cr | ₹4.08 Cr | ₹6.85 Cr | ₹10 Cr |
| Depreciation | ₹12 Cr | ₹10 Cr | ₹6.76 Cr | ₹6.38 Cr | ₹5.44 Cr |
| Profit Before Tax | ₹123 Cr | ₹207 Cr | ₹167 Cr | ₹96 Cr | ₹57 Cr |
| Profit After Tax | ₹90 Cr | ₹152 Cr | ₹124 Cr | ₹73 Cr | ₹39 Cr |
| Consolidated Net Profit | ₹90 Cr | ₹152 Cr | ₹124 Cr | ₹73 Cr | ₹39 Cr |
| Earnings Per Share (Rs) | ₹11.16 | ₹18.86 | ₹16.89 | ₹50.15 | ₹26.93 |
| PAT Margin (%) | 17.40 | 25.80 | 28.68 | 20.41 | 12.27 |
| ROE(%) | 13.66 | 34.34 | 59.17 | 60.42 | 53.11 |
| ROCE(%) | 18.72 | 43.34 | 60.12 | 49.67 | 36.52 |
| Total Debt/Equity(x) | 0.02 | 0.03 | 0.26 | 0.55 | 0.96 |
Key Financials |
||
| Market Cap | : | ₹ 2,950.3 Cr |
| Revenue (TTM) | : | ₹ 570.4 Cr |
| Net Profit(TTM) | : | ₹ 119.1 Cr |
| EPS (TTM) | : | ₹ 14.8 |
| P/E (TTM) | : | 24.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUPRIYA LIFESCIENCE | 1.6% | -12.5% | 38.3% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.5% | -3.8% | 50.8% |
| CIPLA | -2% | 2% | 53.3% |
| DR REDDYS LABORATORIES | -1.7% | -8% | 28.9% |
| ZYDUS LIFESCIENCES | -5.5% | 1.3% | 99.9% |
| DIVIS LABORATORIES | 1.3% | 8.7% | 26.8% |
| MANKIND PHARMA | 1.5% | -8.1% | 53.1% |
| TORRENT PHARMACEUTICALS | 1.6% | 0.9% | 55.9% |
| LUPIN | -1.7% | -3.6% | 95.9% |
SUPRIYA LIFESCIENCE Revenues
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | -13.04 % |
| 5 Yr CAGR | 13.49 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹461 Cr | -13.04 | |
| Mar2022 | ₹530 Cr | 35.49 | |
| Mar2021 | ₹391 Cr | 25.53 | |
| Mar2020 | ₹312 Cr | 12.17 | |
| Mar2019 | ₹278 Cr | - | |
SUPRIYA LIFESCIENCE Operating Profit
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | -39.98 % |
| 5 Yr CAGR | 18.82 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹128 Cr | -39.98 | |
| Mar2022 | ₹214 Cr | 23.59 | |
| Mar2021 | ₹173 Cr | 75.99 | |
| Mar2020 | ₹98 Cr | 52.69 | |
| Mar2019 | ₹64 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -30.96 % |
| 5 Yr CAGR | 4.70 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 27.87% | -30.96 | |
| Mar2022 | 40.37% | -8.79 | |
| Mar2021 | 44.26% | 40.20 | |
| Mar2020 | 31.57% | 36.14 | |
| Mar2019 | 23.19% | - | |
SUPRIYA LIFESCIENCE Profit After Tax
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | -40.81 % |
| 5 Yr CAGR | 22.87 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹90 Cr | -40.81 | |
| Mar2022 | ₹152 Cr | 22.83 | |
| Mar2021 | ₹124 Cr | 68.38 | |
| Mar2020 | ₹73 Cr | 86.19 | |
| Mar2019 | ₹39 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -32.56 % |
| 5 Yr CAGR | 9.13 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 17.4 % | -32.56 | |
| Mar2022 | 25.8 % | -10.04 | |
| Mar2021 | 28.68 % | 40.52 | |
| Mar2020 | 20.41 % | 66.34 | |
| Mar2019 | 12.27 % | - | |
SUPRIYA LIFESCIENCE Earnings Per Share (EPS)
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | -40.83 % |
| 5 Yr CAGR | -19.77 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹11 | -40.83 | |
| Mar2022 | ₹19 | 11.66 | |
| Mar2021 | ₹17 | -66.32 | |
| Mar2020 | ₹50 | 86.22 | |
| Mar2019 | ₹27 | - | |
SUPRIYA LIFESCIENCE Return on Capital Employed (ROCE)
[BOM: 543434|NSE : SUPRIYA]
| Y-o-Y | -56.81 % |
| 5 Yr CAGR | -15.39 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 18.72% | -56.81 | |
| Mar2022 | 43.34% | -27.91 | |
| Mar2021 | 60.12% | 21.04 | |
| Mar2020 | 49.67% | 36.01 | |
| Mar2019 | 36.52% | - | |
SUPRIYA LIFESCIENCE Share Price vs Sensex
| Current Share Price | : | ₹366.5 |
| Current MarketCap | : | ₹ 2,950.3 Cr |
| Updated EOD on | : | May 31,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUPRIYA LIFESCIENCE | 1.6% |
-12.5% |
38.3% |
| SENSEX | -1.9% |
-0.7% |
18.3% |
SUPRIYA LIFESCIENCE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | -1.5% | 0.8% | 58.1% |
| S&P BSE SMALL CAP | -1.5% | -0.1% | 56.7% |
| S&P BSE HEALTHCARE | -1.6% | -1.5% | 48.3% |
| S&P BSE ALLCAP | -1.8% | 0.4% | 35.2% |
No NSE index found
You may also like the below Video Courses
FAQ about SUPRIYA LIFESCIENCE Financials
How the annual revenues of SUPRIYA LIFESCIENCE have changed ?
The Revenues of SUPRIYA LIFESCIENCE have decreased by -13.04% YoY .
How the Earnings per Share (EPS) of SUPRIYA LIFESCIENCE have changed?
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has decreased by -40.83 % YoY .
Check out Intrinsic Value of Peers of SUPRIYA LIFESCIENCE
Compare Stock Analytics of Peers of SUPRIYA LIFESCIENCE
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
